settingsJavascript is not enabled in your browser! This website uses it to optimize the user's browsing experience. If it is not enabled, in addition to causing some web page functions to not operate properly, browsing performance will also be poor!
Yaozi
search
diseaseMalignant Histiocytosis
smart_toy
bubble_chart Overview

Malignant histiocytosis is a malignant disease characterized by abnormal proliferation of histiocytes and their precursor cells. Clinically, it is primarily marked by high fever, splenomegaly, and pancytopenia.

bubble_chart Diagnosis

I. Medical History and Symptoms

1. Medical history inquiry: Pay attention to the onset (acute or gradual) and whether it is accompanied by fever, hepatosplenomegaly, lymphadenopathy, and progressive exhaustion.

2. Clinical symptoms: Dizziness, lack of strength, palpitation, irregular fever (mostly high fever); symptoms of tissue/organ infiltration such as jaundice, skin lesions, serous cavity effusion, etc.

II. Physical Examination Findings

Anemic appearance, possible skin petechiae, ecchymosis, nodules, papules, or ulcers; sternal tenderness; hepatosplenomegaly and lymphadenopathy; jaundice and corresponding signs of histiocytic infiltration into tissues/organs in advanced stages.

III. Auxiliary Examinations

1. Blood test: Progressive pancytopenia; smears may show a small number of abnormal histiocytes, occasionally with immature granulocytes or erythrocytes.

2. Bone marrow examination: Mostly hypercellular, with varying numbers of abnormal histiocytes (generally >10%). The detection of multinucleated giant histiocytes is the main diagnostic criterion. Megakaryocytes are often reduced.

3. Histopathological examination: Destruction of normal tissue structure and infiltration by various abnormal histiocytes confirm the diagnosis.

4. Cytochemical staining: Diffuse positivity for acid phosphatase; negative for Sudan black staining; significantly reduced neutrophil alkaline phosphatase.

IV. Differential Diagnosis

Malignant histiocytosis should be differentiated from reactive histiocytosis, acute leukemia, metastatic bone marrow carcinoma, aplastic anemia, and other diseases.

bubble_chart Treatment Measures

1. Supportive treatment: Same as for acute leukemia.

2. Chemotherapy: CHOP regimen: Cyclophosphamide 600mg/m2, doxorubicin 30mg/m2, vincristine 1.4mg/m2, all administered intravenously on day 1; prednisone 40mg/m2, orally on days 1~5. COPP regimen: The administration method is the same as for lymphoma.

3. Bone marrow transplantation: Eligible patients should undergo allogeneic bone marrow transplantation, which may cure some patients.

AD
expand_less